Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: High Fat

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 24 results found since Jan 2013.

NmFGF1-Regulated Glucolipid Metabolism and Angiogenesis Improves Functional Recovery in a Mouse Model of Diabetic Stroke and Acts via the AMPK Signaling Pathway
Diabetes increases the risk of stroke, exacerbates neurological deficits, and increases mortality. Non-mitogenic fibroblast growth factor 1 (nmFGF1) is a powerful neuroprotective factor that is also regarded as a metabolic regulator. The present study aimed to investigate the effect of nmFGF1 on the improvement of functional recovery in a mouse model of type 2 diabetic (T2D) stroke. We established a mouse model of T2D stroke by photothrombosis in mice that were fed a high-fat diet and injected with streptozotocin (STZ). We found that nmFGF1 reduced the size of the infarct and attenuated neurobehavioral deficits in our mous...
Source: Frontiers in Pharmacology - May 7, 2021 Category: Drugs & Pharmacology Source Type: research

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of fingolimod. Stroke was induced via middle cerebral artery electrocoagulation in 8–9-week old mice (young mice), 18 month old mice (aged mice), and in high-fat diet-fed 22-week old ApoE−/− mice (hyperlipidaemic mice). Recovery was evaluated using motor behavioural tests 3 and 7 days after stroke. Tissue damage was evaluated at 7 days. A lower dose of fingolimod, 0.5 mg/kg, but not 1 mg/kg, increased lesion size but decreased ipsilateral brain at...
Source: Frontiers in Pharmacology - July 13, 2022 Category: Drugs & Pharmacology Source Type: research

NLRP3 Inflammasome Inhibition with MCC950 Improves Diabetes-Mediated Cognitive Impairment and Vasoneuronal Remodeling After Ischemia
Publication date: Available online 25 February 2019Source: Pharmacological ResearchAuthor(s): Rebecca Ward, Weiguo Li, Yasir Abdul, LaDonya Jackson, Guangkuo Dong, Sarah Jamil, Jessica Filosa, Susan C. Fagan, Adviye ErgulAbstractDiabetes increases the risk and worsens the progression of cognitive impairment via the greater occurrence of small vessel disease and stroke. Yet, the underlying mechanisms are not fully understood. It is now accepted that cardiovascular health is critical for brain health and any neurorestorative approaches to prevent/delay cognitive deficits should target the conceptual neurovascular unit (NVU) ...
Source: Pharmacological Research - February 26, 2019 Category: Drugs & Pharmacology Source Type: research

DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE < sup > -/- < /sup > mice via suppressing inflammation, endothelial necroptosis and apoptosis
This study aims to explore whether NBP is able to improve endothelium-dependent vasodilation in atherosclerosis and the underlying mechanisms. Male ApoE-/- mice were fed with a high-fat diet (HFD) for 9-16 weeks to establish a model of atherosclerosis. NBP were given to the mice after eating HFD for 6 weeks and atorvastatin served as a positive control. The endothelium-dependent vasodilation, the blood flow velocity, the atherosclerotic lesion area, the serum levels of lipids, inflammatory cytokines and necroptosis-relevant proteins (RIPK1, RIPK3 and MLKL), and the endothelial necroptosis and apoptosis within the aorta wer...
Source: European Journal of Pharmacology - August 3, 2023 Category: Drugs & Pharmacology Authors: Li-Qun Lu Nian-Sheng Li Ming-Rui Li Jiao-Yang Peng Li-Jing Tang Xiu-Ju Luo Jun Peng Source Type: research

Chymase inhibitor prevents the development and progression of  non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet
Publication date: Available online 20 June 2017 Source:Journal of Pharmacological Sciences Author(s): Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Koji Komeda, Shinsuke Masubuchi, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama The effect of the chymase inhibitor TY-51469 on the development and progression of non-alcoholic steatohepatitis (NASH) was evaluated in rats fed a high-fat and high-cholesterol (HFC) diet. To evaluate the preventive effect of TY-51469 on the development of NASH, stroke-prone spontaneously hypertensive rat 5 (SHRSP5)/Dmcr rats were fed either a normal or HFC diet for 8 weeks, an...
Source: Journal of Pharmacological Sciences - July 1, 2017 Category: Drugs & Pharmacology Source Type: research

Proteomic analysis reveals the renoprotective effect of Tribulus terrestris against obesity-related glomerulopathy in rats.
In conclusion, TT may play a protective role against ORG in rats. PMID: 29984733 [PubMed - as supplied by publisher]
Source: Biological and Pharmaceutical Bulletin - July 6, 2018 Category: Drugs & Pharmacology Authors: Jiang YH, Jiang LY, Wu S, Jiang WJ, Xie L, Li W, Yang CH Tags: Biol Pharm Bull Source Type: research

6-Bromoindirubin-3 ′-Oxime (6BIO) Suppresses the mTOR Pathway, Promotes Autophagy, and Exerts Anti-aging Effects in Rodent Liver
In this study, we aimed to investigate the anti-aging effect, and molecular mechanism, of the novel anti-aging drug 6BIO on naturally aged mouse liver. Rapamycin, a well-known promising anti-aging drug that delays aging through mTOR-dependent autophagy (Zhou and Ye, 2018), was used as the positive control in the study. To our knowledge, this is the first study to demonstrate the effects of 6BIO treatment in models of natural aging. Our results indicated that 6BIO ameliorates the decline of liver function with age, including lipid metabolism disorder, and attenuates hepatocyte senescence in aged mice, as revealed by altera...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Nrf2 as a Potential Mediator of Cardiovascular Risk in Metabolic Diseases
Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Genetics of hyperhomocysteinemia and 1-carbon metabolism: implications for retinal structure and eye functions.
Abstract Homocysteine (Hcy); a sulfur-containing non-proteinogenic amino acid is generated as a metabolic intermediate. Hcy constitutes an important part of the "1-carbon metabolism" during methionine turnover. Elevated levels of Hcy known as hyperhomocysteinemia (HHcy) results from vitamin B deficiency, lack of exercise, smoking, excessive alcohol intake, high fat and methionine rich diet, and the underlying genetic defects. These factors directly affect the "1-carbon metabolism (methionine-Hcy-folate)" of a given cell. In fact, the Hcy levels are determined primarily by dietary intake, vitamin status, and the ge...
Source: Canadian Journal of Physiology and Pharmacology - July 31, 2019 Category: Drugs & Pharmacology Authors: George AK, Majumder A, Ice H, Homme RP, Eyob W, Tyagi SC, Singh M Tags: Can J Physiol Pharmacol Source Type: research

Use of a bioengineered antioxidant in mouse models of metabolic syndrome.
Conclusions: PEG-HCC can improve some parameters of disease in these models and this may be due to a resulting increase in peripheral insulin sensitivity. However, additional studies are needed to elucidate how PEG-HCCs are producing these effects. PMID: 31937152 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - January 17, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research

Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury
Biomed Pharmacother. 2021 Feb 27;138:111441. doi: 10.1016/j.biopha.2021.111441. Online ahead of print.ABSTRACTMetabolic syndrome (MetS) is a complex, multifactorial disease which lead to an increased risk of cardiovascular disease, type 2 diabetes, and stroke. However, selective, and potent drugs for the treatment of MetS are still lacking. Previous studies have found that Akebia saponin D (ASD) has beneficial effects on metabolic diseases such as obesity, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). Therefore, our study was designed to determine the effect and mechanism of action of ASD against MetS in ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 2, 2021 Category: Drugs & Pharmacology Authors: Song Yang Ting Hu He Liu Ya-Li Lv Wen Zhang Han Li Lingling Xuan Li-Li Gong Li-Hong Liu Source Type: research

Low-Dose Piperlongumine Rescues Impaired Function of Endothelial Progenitor Cells and Reduces Cerebral Ischemic Injury in High-Fat Diet-Fed Mice
In conclusion, low-dose piperlongumine can enhance EPCs’ angiogenic potential and protect against cerebral ischemic injury in HFD-fed mice. It is implied that treatment with low-dose piperlongumine might be a potential option to prevent ischemic diseases (including stroke) in patients with hyperlipidemia, and priming with piperlongumine might be a feasible way to improve the efficacy of EPC-based therapy for ischemic diseases.
Source: Frontiers in Pharmacology - November 15, 2021 Category: Drugs & Pharmacology Source Type: research